EPR (electron paramagnetic resonance) has been used to study interactions of the Ru(III) anticancer compounds imidazolium [trans-RuCl4(1H-imidazole)(DMSO-S)] (NAMI-A) and indazolium [trans-RuCl4(1H-indazole)2] (KP1019) with isolated subcellular components and whole cells of the yeast Saccharomyces cerevisiae. These studies are the first to probe the intracellular speciation of ruthenium using t...

Based on the clinical success of platinum-based anti-cancer drugs such as cisplatin, carboplatin and oxaliplatin, a variety of other metal-based anti-cancer compounds are being investigated. In particular, a number of ruthenium-based compounds have been identified which exhibit unique biochemical properties and reduced toxicity profiles compared to the clinically used platinum-based drugs. We h...

Homo- and heteroleptic bis-tridentate ruthenium(II) and osmium(II) complexes of compositions [(tpy-PhCH(3))Ru(tpy-HImzPh(3))](ClO(4))(2) (1), [(H(2)pbbzim)Ru(tpy-HImzPh(3))] (ClO(4))(2) (2) and [M(tpy-HImzPh(3))(2)](ClO(4))(2) [M = Ru(II) (3) and Os(II) (4)], where tpy-PhCH(3) = p-methylphenyl terpyridine, H(2)pbbzim = 2,6-bis(benzimidazole-2-yl)pyridine and tpy-HImzPh(3) = 4'-[4-(4,5-diphenyl-...

Significant advances in the use of metal complexes, precipitated by platinum, have fostered a renewed interest in harnessing their rich potential in the treatment of cancer. In addition to platinum-based complexes, the anticancer properties of other metals such as ruthenium have been realized, and ruthenium-based compounds are currently being investigated in clinical trials. Since the process o...

The ruthenium complexes are known for their anticancer property. Some ruthenium complexes can bind with protein that may be related to the anticancer activity. The protein binding features of few ruthenium complexes have been analyzed to understand the amino acid selectivity within protein sequences. The docking, Molecular mechanics and QM/MM methods are used to predict the binding sites of the...

Enantiopure dinuclear ruthenium polypyridyl complexes of the form [Ru(2)(LL)(4)L(1)](PF(6))(4) (LL = 2,2'-bipyridine (bpy) or 1,10-phenanthroline (phen); L(1)= C(25)H(20)N(4) a bis(pyridylimine) ligand containing a diphenylmethane spacer) have been synthesized using the chiral building blocks cis-[Ru(bpy)(2)(py)(2)](2+) and cis-[Ru(phen)(2)(py)(2)](2+). These dinuclear ruthenium complexes have ...

Organometallic compounds offer broad scope for the design of therapeutic agents, but this avenue has yet to be widely explored. A key concept in the design of anticancer complexes is optimization of chemical reactivity to allow facile attack on the target site (e.g., DNA) yet avoid attack on other sites associated with unwanted side effects. Here, we consider how this result can be achieved for...

Over 4.5 billion people are at risk of infection with soil transmitted helminths and there are concerns about the development of resistance to the handful of frontline nematocides in endemic populations. We investigated the anti-nematode efficacy of a series of polypyridylruthenium(II) complexes and showed they were active against L3 and adult stages of Trichuris muris, the rodent homologue of ...

The reactions of ruthenium trichloride with Schiff bases derived from sulpha drugs in 1:2 molar ratio leads to the formation of a new series of coordination compounds of type [Ru(L) 2 (H 2 O)Cl]. The Schiff bases used here are o-Vanillin sulphanilamide (oVSaH), o-Vanillin sulphamerazine (oVSmrzH), salicylaldehyde sulphanilamide (SdSaH), salicylaldehyde sulphamerazine (SdSmrzH), 2-hydroxy-1-naph...

Metals such as platinum, gold, ruthenium, titanium and tin can be a source of biologically active derivatives and, occasionally, become tools in the chemotherapy against different kinds of human tumors. The preclinical evaluation includes not only antitumor activity tests but also the investigation of the particular chemistry, the molecular targets within biological materials and the effect on ...